Cholangitis

AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…

Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line…

Women with primary biliary cholangitis (PBC) may be at increased risk of having disease flares in the months following childbirth, according to a small…

A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver disease is among those being…

Aramchol, a small molecule in the Galmed Pharmaceuticals pipeline, prevented and reversed inflammation and scarring (fibrosis) of the bile ducts in mouse models of…

The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…

October is National Liver Awareness Month and Liver Cancer Awareness Month, and advocacy organizations across the U.S., including the American Liver Foundation (ALF), are…

Adults with autoimmune liver disease experience lower quality of life, especially those with primary biliary cholangitis (PBC), who report more fatigue, sleepiness, and pain…

Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to…

Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…